RBC Capital cuts uniQure stock price target on trial data
RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.
How this was made
The 30-second read
Why it matters
Analyst target reduction and missed statistical significance are new, material facts that can drive short‑term price moves.
Market read
The downgrade and trial miss provide a clear catalyst for QURE's near‑term price action and may influence sentiment across the biotech sector.
What to watch
Potential upcoming regulatory interactions and the breakthrough therapy designation could still support long‑term upside.
Background
The article summarizes recent analyst actions and trial data for uniQure, a Nasdaq‑listed gene‑therapy company developing AMT‑130 for Huntington's disease.
Ticker impact
RBC Capital lowered its price target on uniQure to $48 after the company's four-year trial data missed statistical significance on the primary endpoint.
likely pressure as the market prices in the reduced target and missed trial significance
Analyst target cut and missed primary endpoint are fresh, material information that directly affect valuation.
Market effects
Biotech and gene‑therapy sector may see broader risk reassessment on Huntington's disease programs.
U.S. biotech stocks could face short‑term weakness.
Limited to investors focused on clinical‑trial outcomes and gene‑therapy pipelines.
Counterpoint
Some investors may view the price target cut as an overreaction if later data improve the therapy's profile.
Key entities
- CompanyuniQure BV
NASDAQ-listed biotech developing gene‑therapy for Huntington's disease.
- AnalystRBC Capital
Equity research firm that lowered the price target.
